These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
611 related articles for article (PubMed ID: 28361189)
1. Personalized Del Prete M; Buteau FA; Beauregard JM Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189 [TBL] [Abstract][Full Text] [Related]
2. Personalized Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283 [TBL] [Abstract][Full Text] [Related]
3. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized Del Prete M; Arsenault F; Saighi N; Zhao W; Buteau FA; Celler A; Beauregard JM EJNMMI Phys; 2018 Oct; 5(1):25. PubMed ID: 30318563 [TBL] [Abstract][Full Text] [Related]
4. Salvage peptide receptor radionuclide therapy with [ van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116 [TBL] [Abstract][Full Text] [Related]
5. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852 [TBL] [Abstract][Full Text] [Related]
6. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function. Ranade R; Basu S J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166 [TBL] [Abstract][Full Text] [Related]
7. Prospective observational study of Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803 [TBL] [Abstract][Full Text] [Related]
15. Safety of multiple repeated cycles of Yordanova A; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Essler M; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1207-1214. PubMed ID: 28246882 [TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623 [TBL] [Abstract][Full Text] [Related]
17. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212 [TBL] [Abstract][Full Text] [Related]
18. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [ Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of peptide receptor radionuclide therapy with Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700 [TBL] [Abstract][Full Text] [Related]
20. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Parghane RV; Talole S; Prabhash K; Basu S Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]